PARP inhibitors are used as tumor therapy drugs, specifically targeting cancer cells with genetic defects in DNA repair genes such as BRCA1, exploiting their synthetic lethal relationship with PARP1 (Mateo et al, 2019). Here, PARP1 is linked to neoplasm.